110results about How to "Reduce cell viability" patented technology

Provided is a method for preparing a fecal sample which can stably store a nucleic acid contained in feces without the need of any complicated procedure. Also disclosed is a fecal sample preparation solution to be used in the method. Further disclosed is a feces collection kit. Still further disclosed is a method for collecting a nucleic acid from feces by using a fecal sample prepared by the above-mentioned method and analyzing the nucleic acid. Feces collected is mixed with a fecal sample preparation solution containing, as an active ingredient, a water-soluble organic solvent containing an organic acid, thereby preparing a fecal sample which can store a nucleic acid contained therein satisfactorily.

Dehydrated, edible, high-protein food products formed of cultured muscle cells that are combined (e.g., mixed) with a hydrogel (e.g., a plant-derived polysaccharide) are described. These food products may be formed into a chip (e.g., snack chip), that has a protein content of greater than 50%. One or more flavorants may also be included.

The present invention generally provides vectors, compositions, and methods of using the same for treating neurological disorders, including managing pain. The compositions and methods include the use of G protein-coupled receptors and ligand-gated ion channels to treat neurological indications including pain, epilepsy and satiety disorders. The compositions and methods further include the use of synthetic ligands to activate the G protein-coupled receptors and ligand-gated ion channels in the treatment of neurological disease.

The invention provides a method that uses enzyme-treatment of whole soybeans or partially defatted soybeans to select soybeans with improved bioactivity or bioactivities. The invention further provides a soybean plant and seed with a non-transgenic mutation conferring enhanced bioactivity as an hydrolysate when compared to hydrolysate from other seeds, for instance in a cell-based assay, including reduced cancer cell viability; increased LDL receptor activity; reduced lipid accumulation; increased adiponectin expression; decreased FAS and LPL expression; reduced production of NO and PGE2, and expression of iNOS and COX-2; higher antioxidant activity; promotion of growth of bifidobacteria; and inhibiting the growth of pathogenic bacteria; for instance when compared to other seeds tested as hydrolysates. The invention also provides soybean plants for use in producing seeds that have an overall improved bioactivity compared to other seeds as hydrolysates by combining effects on several bioactivity assays in a health index. The invention also provides products derived from, and parts of, these plants and uses thereof. Methods for producing such plants are also provided, as well as methods for standardizing or assuring quality control of soybean products with enhanced bioactivity for humans and animals.

The present invention provides for methods and devices suitable for producing a transplantable cellular suspension of living tissue suitable for grafting to a patient. In applying the method and / or in using the device, donor tissue is harvested, subjected to a cell dissociation treatment, cells suitable for grafting back to a patient are collected and dispersed in a solution that is suitable for immediate dispersion over the recipient graft site.

A pharmaceutical composition containing hyaluronan as an active ingredient is provided. A preferred hyaluronan is a tetrasaccharide (HA4) containing 2 units, with a single unit being -D-glucuronic acid-β-1,3-D-N-acetylglucosamine-β-1,4-.

When a mutation, designated rad51M1, was generated in the mouse MmRAD51 gene, mutant embryos died shortly after implantation. rad51M1 cells exhibited hypersensitivity to ionizing radiation, reduced proliferation, programmed cell death and chromosome loss. The disruption of MmRad51 protein-protein interactions stopped cell proliferation and / or reduced cell viability. Several proteins that interact with MmRad51 have been identified including, for example Brca2 and M96. Additionally, Rad51 self-associates via the N-terminal region. When a single residue was changed from a conserved lysine to an alanine, the alteration proved toxic to cells. Moreover, a rad51 allele that lacked the RecA homology region was also deleterious to cells. In view of the above, it is clear that inhibiting MmRad51 function or the function of any molecule that associates with MmRad51, or any molecule in the Rad51 or Rad52 pathways, hinders cell proliferation and / or viability. Accordingly, molecules capable of blocking these critical DNA repair pathways may be effective as therapeutics for inhibiting cell proliferation.

Provided are methods and compositions for maintaining the viability of photoreceptor cells and / or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and / or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder.

The present invention provides novel targets in eukaryotic cells for antibiotic agents and methods for identification of antibiotic agents affecting such targets and the use of the identified antibiotic agents in treatment of opportunistic infections in eukaryotic hosts. The invention is based upon the identification of species specific 5′ hinge and 3′ hinge regions of U3 small nucleolar ribonucleic acid (snoRNA). The present invention discloses that the external transcribed spacer (ETS) of the ribosomal RNA precursor (pre-rRNA) comprises sequences that are complementary to the 5′ and 3′ hinge regions of U3 snoRNA. The invention further discloses that sequence substitutions of the 5′ hinge or 3′ hinge region of U3 snoRNA severely compromise or fully inhibit the cleavage events at sites 1 and 2 in rRNA processing necessary to form mature 18S rRNA which is a vital component of the small subunit of ribosomes of all eukaryotes.